Merck tops quarterly estimates, hikes profit outlook as new form of Keytruda shows strength

Merck topped third-quarter estimates and hiked its adjusted profit outlook. The company's immunotherapy Keytruda, including a newer injectable form of the drug called Qlex, posted stronger-than-expected sales.

CNBC • 13 hours ago

Merck's Keytruda Franchise Expands, Signals 'Modest' Revenue Growth in 2027

Merck & Co. Inc. (NYSE:MRK) stock edged higher Thursday after the drugmaker reported third-quarter results that topped Wall Street revenue expectations and upbeat financial guidance.

Benzinga • 6 hours ago

Merck Lifts Outlook on a Lower Tax Rate: Rapid Earnings Reaction

Newer drugs are scaling fast enough to offset generic losses. Merck's third-quarter sales rose 5% to about $18.1 billion, but roughly $550 million of that came from the timing of customer purchases, so underlying growth was close to flat.

The Motley Fool • 5 hours ago

Merck Beats, But Can Shares Outplay The Cancer Vaccine News?

Dow Jones component Merck hiked its 2026 outlook Thursday on the back of a solid third-quarter report that included a notable Keytruda beat.

Investors Business Daily • 13 hours ago

Merck Earnings Blow Past Estimates. Why Wall Street Is Looking Past the Numbers.

Merck is leaning on newer drugs and the promise of its pipeline assets as a patent cliff looms for its largest revenue driver, Keytruda.

Barrons • 13 hours ago

Merck: A Strong Quarter, But It's Time To Take A Step Back

In the third quarter, Merck & Co., Inc.'s revenue grew 8.9% QoQ. Sales of Keytruda+Keytruda Qlex, its PD-1 immune checkpoint inhibitors, reached $8.1 billion, up 5.6% YoY and 2.8% QoQ. Winrevair, its activin signaling inhibitor for pulmonary arterial hypertension, also performed well, generating $694 million in net revenue, up 18% sequentially.

Seeking Alpha • 10 hours ago

Merck & Co., Inc. (MRK) Q3 2026 Earnings Call Transcript

Merck & Co., Inc. (MRK) Q3 2026 Earnings Call Transcript

Seeking Alpha • 6 hours ago

Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline

RAHWAY, N.J.--(BUSINESS WIRE)--Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline.

Business Wire • 13 hours ago

Merck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges Higher

Merck (NYSE:MRK | MRK Price Prediction) is the second big drugmaker to reward investors with an earnings beat and a raised profit outlook.

24/7 Wall Street • 9 hours ago

Merck (MRK) Surpasses Q3 Earnings and Revenue Estimates

Merck (MRK) came out with quarterly earnings of $2.49 per share, beating the Zacks Consensus Estimate of $2.12 per share. This compares to earnings of $2.58 per share a year ago.

Zacks Investment Research • 11 hours ago